Distribution of effervescent inhalable nanoparticles after pulmonary delivery: An in vivo study

Therapeutic Delivery

Volumn 3, Issue 6, 2012, Pages 725-734

  Al Hallak, M H D Kamal ^a,b   Sarfraz, Muhammad K ^a,c   Azarmi, Shirzad ^a,d   Roa, Wilson H ^a   Finlay, Warren H ^a   Rouleau, Claude ^e   Löbenberg, Raimar ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b DAMASCUS UNIVERSITY   (Syrian Arab Republic)

^c THE ISLAMIA UNIVERSITY OF BAHAWALPUR   (Pakistan)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e MAURICE LAMONTAGNE INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; DOXORUBICIN; FLUORESCEIN ISOTHIOCYANATE; NANOCARRIER; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RELEASE; DRUG RETENTION; DRUG SAFETY; FEMALE; IMAGE ANALYSIS; IN VIVO STUDY; ISOLATED LUNG; LUNG CANCER; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RADIOACTIVITY; WHOLE BODY AUTORADIOGRAPHY; ZETA POTENTIAL;

EID: 84861834609     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.12.42     Document Type: Article

References (42)

1. O'Connor SJ. Review of the incidence, prevalence, mortality and causative factors for lung cancer in Europe. Eur. J. Cancer 47(Suppl. 3), S346-S347 (2011).
2. Soerjomataram I, Barendregt JJ, Gartner C, Kunst A, Moller H, Avendano M. Reducing inequalities in lung cancer incidence through smoking policies. Lung Cancer 73(3), 268-273 (2011).
3. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: Epidemiology, etiology, and prevention. Clin. Chest Med. 32(4), 605-644 (2011).
4. Mcerlean A, Ginsberg MS. Epidemiology of lung cancer. Semin. Roentgenol. 46(3), 173-177 (2011).
5. Hazarika M, White RM, Johnson JR, Pazdur R. FDA drug approval summaries: Pemetrexed (Alimta). Oncologist 9(5), 482-488 (2004).
6. Cohen MH, Williams GA, Sridhara R, Chen G, Pazdur R. FDA drug approval summary: Gefitinib (ZD1839) (Iressa) tablets. Oncologist 8(4), 303-306 (2003).
7. Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R. FDA drug approval summary: Erlotinib (Tarceva) tablets. Oncologist 10(7), 461-466 (2005).
8. Eaton KD, Martins RG. Maintenance chemotherapy in non-small cell lung cancer. J. Natl Compr. Canc. Netw. 8(7), 815-821 (2010).
9. Kim YH, Mishima M. Maintenance chemotherapy for non-small-cell lung cancer. Cancer Treat. Rev. 37(7), 505-510 (2011).
10. Roa WH, Azarmi S, Al-Hallak MH, Finlay WH, Magliocco AM, Lobenberg R. Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model. J. Control. Release 150(1), 49-55 (2011).
11. Verdun C, Brasseur F, Vranckx H, Couvreur P, Roland M. Tissue distribution of doxorubicin associated with polyisohexylcyanoacrylate nanoparticles. Cancer Chemother. Pharmacol. 26(1), 13-18 (1990).
12. Payan JP, Binet S, Beydon D, Ferrari E. Bio-distribution study of 1,2-diethylbenzene and its main metabolites by whole-body autoradiography and tissue homogenates. Arch. Toxicol. 82(9), 591-600 (2008).
13. Paddock SW Confocal laser scanning microscopy. Biotechniques 27(5), 992-996, 998-1002, 1004 (1999).
14. Azarmi S, Tao X, Chen H et al. Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles. Int. J. Pharm. 319(1-2), 155-161 (2006).
15. Microcalorimetric method to assess phagocytosis: Macrophage-nanoparticle interactions. AAPS J. 13(1), 20-29 (2011).
16. Azarmi S, Lobenberg R, Roa WH, Tai S, Finlay WH. Formulation and in vivo evaluation of effervescent inhalable carrier particles for pulmonary delivery of nanoparticles. Drug Dev. Ind. Pharm. 34(9), 943-947 (2008).
17. Cheow WS, Ng ML, Kho K, Hadinoto K. Spray-freeze-drying production of thermally sensitive polymeric nanoparticle aggregates for inhaled drug delivery: Effect of freeze-drying adjuvants. Int. J. Pharm. 404(1-2), 289-300 (2011).
18. Al-Hallak MH, Azarmi S, Sun C et al. Pulmonary toxicity of polysorbate-80-coated inhalable nanoparticles; in vitro and in vivo evaluation. AAPS J. 12(3), 294-299 (2010).
19. Rouleau C, Kohli J. Distribution of 14C-labelled atrazine, methoxychlor, glyphosate and bisphenol-A in goldfish studied by whole-body autoradiography (WBARG). Water Qual. Res. J. Can. 43(4), 265-274 (2008).
20. Rouleau C, Xiong ZH, Pacepavicius G, Huang GL. Uptake of waterborne tributyltin in the brain of fish: Axonal transport as a proposed mechanism. Environ. Sci. Technol. 37(15), 3298-3302 (2003).
21. Calvo PL Vila-Jato JL, Alonso MJ. Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers. J. Pharm. Sci. 85(5), 530-536 (1996).
22. Cosco D, Celia C, Cilurzo F, Trapasso E, Paolino D. Colloidal carriers for the enhanced delivery through the skin. Expert Opin. Drug Deliv. 5(7), 737-755 (2008).
23. Azarmi S, Roa WH, Lobenberg R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv. Drug Deliv. Rev. 60(8), 863-875 (2008).
24. Pulmonary delivery of inhalable nanoparticles: Dry powder inhalers. Therapeutic Delivery 2(10), 1313-1324 (2011).
25. Kaialy W, Alhalaweh A, Velaga SP, Nokhodchi A. Effect of carrier particle shape on dry powder inhaler performance. Int. J. Pharm. 421(1), 12-23 (2011).
26. Sung JC, Pulliam BL, Edwards DA. Nanoparticles for drug delivery to the lungs. Trends Biotechnol. 25(12), 563-570 (2007).
27. Suk JS, Lai SK, Boylan NJ, Dawson MR, Boyle MP, Hanes J. Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-Acetyl cysteine. Nanomedicine (Lond.) 6(2), 365-375 (2011).
28. Gelperina S, Kisich K, Iseman MD, Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am. J. Respir. Crit. Care Med. 172(12), 1487-1490 (2005).
29. Elder A, Gelein R, Silva V et al. Translocation of inhaled ultrafine manganese oxide particles to the central nervous system. Environ. Health Perspect. 114(8), 1172-1178 (2006).
30. Al-Hallak KM, Azarmi S, Anwar-Mohamed A, Roa WH, Lobenberg R. Secondary cytotoxicity mediated by alveolar macrophages: A contribution to the total efficacy of nanoparticles in lung cancer therapy? Eur. J. Pharm. Biopharm. 76(1), 112-119 (2010).
31. Sung JC, Padilla DJ, Garcia-Contreras L et al. Formulation and pharmacokinetics of self-Assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm. Res. 26(8), 1847-1855 (2009).
32. Tomoda K, Ohkoshi T, Hirota K et al. Preparation and properties of inhalable nanocomposite particles for treatment of lung cancer. Colloids Surf. B Biointerfaces 71(2), 177-182 (2009).
33. Furuyama A, Kanno S, Kobayashi T, Hirano S. Extrapulmonary translocation of intratracheally instilled fine and ultrafine particles via direct and alveolar macrophage-Associated routes. Arch. Toxicol. 83(5), 429-437 (2009).
34. Videira MA, Botelho MF, Santos AC, Gouveia LF, De Lima JJ, Almeida AJ. Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J. Drug Target. 10(8), 607-613 (2002).
35. O'Byrne K. The link between inflammation and cancer: Wounds that do not heal. Angus GD, Burkhard H (Eds). Springer, New York, NY, USA (2006).
36. Montuenga LM, Pio R. Tumour-Associated macrophages in nonsmall cell lung cancer: The role of interleukin-10. Eur. Respir. J. 30(4), 608-610 (2007).
37. Condeelis J, Pollard JW. Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis. Cell 124(2), 263-266 (2006).
38. Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol. Oncol. 26(1), 57-64 (2008).
39. Kante B, Couvreur P, Lenaerts V. Tissue distribution of [3H] actinomycin D adsorbed on polybutylcyanoacrylate nanoparticles. Int. J. Pharm. 7(1), 45-53 (1980).
40. Johansen PB. Doxorubicin pharmacokinetics after intravenous and intraperitoneal administration in the nude mouse. Cancer Chemother. Pharmacol. 5(4), 267-270 (1981).
41. Wartenberg M, Acker H. Induction of cell death by Doxorubicin in multicellular spheroids as studied by confocal laser scanning microscopy. Anticancer Res. 16(2), 573-579 (1996).
42. Lenaerts V, Couvreur P, Christiaens-Leyh D et al. Degradation of poly (isobutyl cyanoacrylate) nanoparticles. Biomaterials 5(2), 65-68 (1984).